U.S. markets close in 5 hours 13 minutes

iShares Nasdaq Biotechnology ETF (IBB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
131.73-0.63 (-0.48%)
As of 10:46AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close132.36
Open132.55
Bid131.59 x 1800
Ask131.58 x 1000
Day's Range130.97 - 132.92
52 Week Range92.15 - 146.53
Volume652,629
Avg. Volume2,815,189
Net Assets9.52B
NAV132.39
PE Ratio (TTM)N/A
Yield0.23%
YTD Daily Total Return12.34%
Beta (5Y Monthly)1.01
Expense Ratio (net)0.47%
Inception Date2001-02-05
  • MarketWatch

    Biosig stock plunges to lead Nasdaq losers after trial of COVID-19 treatment halted

    Shares of Biosig Technologies Inc. plunged 39.0% in active morning trading Monday, enough to pace all Nasdaq decliners, after the medical technology company halted a trial of its COVID-19 treatment given disappointing results. Trading volume was 2.0 million shares, already nearly triple the full-day average of about 693,000 shares. The company's oral merimepodib, in combination with intravenous remdesivir in adult patients with advanced COVID-19 was undergoing a Phase 2 trial. The company said that all 22 grade 4 patients discharged from the hospital did not relapse during the 37-day follow-up period, but grade 3 patients had "markedly" different outcomes. "Specifically, the unblinded [Safety Monitoring Committee) detected an imbalance in survival rates in these NIAID Grade 3 patients between the placebo and merimepodib making it unlikely that the trial would meet its primary safety endpoints," the company stated. Therefore, Biosig elected to stop enrollment in the trial, and does not intend to further develop merimepodib. The stock has shed 48.3% year to date, while the iShares Nasdaq Biotechnology ETF has climbed 11.9% and the S&P 500 has gained 5.2%.

  • MarketWatch

    Aptinyx stock soars on premarket leading volume after positive trial results of PTSD treatment

    Shares of Aptinyx Inc. shot up 61% on heavy volume in premarket trading Tuesday, putting them on track to open at a 20-month high, after the biopharmaceutical company reported positive results from a Phase 2 trial of its treatment for post-traumatic stress disorder (PTSD). Trading volume was 14.6 million shares, making the stock the most actively traded ahead of the open, and compared with the full-day average of about 269,000 shares. The company said its NYX-783 demonstrated "statistically significant and clinically meaningful efficacy results and a favorable adverse event and tolerability profile." As a result, the company expects to initiate a pivotal study in 2021. The stock, which is on track to open at the highest price seen during regular-session hours since February 2019, has gained 7.0% year to date through Monday, while the iShares Nasdaq Biotechnology ETF has rallied 14.0% and the S&P 500 has advanced 6.1%.

  • MarketWatch

    Aligos Therapeutics stock rallies out of the gate, then pulls back

    Shares of Aligos Therapeutics Inc. rallied out of the gate Friday, as they opened 16% above the initial public offering price. The stock's first trade on the Nasdaq was at $17.40 at 1:33 p.m. Eastern for 485,960 shares. The IPO was priced late Thursday at $15 a share, in the middle of the expected range of between $14 and $16 a share. The California-based biopharmaceutical company focused on viral and liver disease treatments raised $150 million in the IPO, and the pricing valued that company at about $540.8 million. The stock has pulled back since the opening, as it hit an intraday low of $13.63, or 9.1% below the IPO price, before bounding to be up 0.6% in afternoon trading. The company has gone public at a time of strong investor demand for IPOs, as the Renaissance IPO ETF has soared 32.6% over the past three months, while the iShares Nasdaq Biotechnology ETF has slipped 0.8% and the S&P 500 has gained 9.0%.